Breaking News

An advisory board defects over Alzheimer's drug; what's next for Roche

  

 

Pharmalot Ed Silverman

STAT+: Advocacy group's advisory board members defect over Biogen Alzheimer's drug

By Ed Silverman

Adobe

The furious debate over the Alzheimer's drug Aduhelm has now sparked controversy over the Alliance for Aging Research.

Read More

'We are not casting a wide enough net': Rob Perez on how biopharma companies can help out their neighbors

By Andrew Joseph

Alex Hogan/STAT

"Most biotech companies are small, not profitable yet, and most of them don't have the resources to have significant philanthropic efforts."

Read More

Listen: What's next for Roche, a debate over second boosters, & Vertex's recent success

By Adam Feuerstein and Meg Tirrell

STAT's Andrew Joseph joins us to discuss an FDA advisory panel meeting that weighed Covid-19 boosters and the potential for updated vaccines.

Read More

Opinion: 3 steps ARPA-H needs to take to accomplish its mission

By Travis Whitfill

Adobe

ARPA-H didn't get the funding or independence many pushed for, but it can still emulate DARPA's structure and principles.

Read More

Thursday, April 7, 2022

STAT

Facebook   Twitter   YouTube   Instagram

1 Exchange Pl, Suite 201, Boston, MA 02109
©2022, All Rights Reserved.
I no longer wish to receive STAT emails
Update Email Preferences | Contact Us | View In Browser

No comments